Breast Reconstruction in Jordan
Breast Reconstruction in Jordan section, includes general infrmation about Breast Reconstruction Procedure, Breast Reconstruction Jordan Local News, Breast Reconstruction Jordan Surgeon Locator and other Breast Reconstruction related material.
Breast Reconstruction Procedure
This procedure is designed for women who underwent breast amputation after breast cancer or other conditions. Newer techniques allow the surgeon to create a breast which is very similar to the natural one. The reconstruction can be done during the amputation procedure, or a few months or even a year afterwards.
There are a number of implants: the most widely used are silicon implants which have silicon surface and filling. They come in different sizes and shapes.
Becker implants are made of a thick silicon surface (35%-50%) and a solution filling. The advantage of this implant is the ability to adjust its shape to the woman's body. It can also serve as a skin stretcher. There are also implants with a thin silicon surface and a solution filling, which are less used.
The operation can be divided into 2 main categories: (a) a stretcher is inserted, then replaced with an implant; (b) the reconstruction is made from another body tissue.
The most common reconstruction is performed with a stretcher and an implant. After amputation a balloon (stretcher) is inserted under the skin and chest muscles. It has a special valve which can be filled from outside. The implant is being filled gradually with a special solution, until the skin has sufficiently stretched for inserting the implant. It takes another 3-6 months until the breast has acquired its final shape, then the nipple can be reconstructed as well.
Becker implants: sometimes during amputation the skin can be preserved. That would eliminate the need for a stretcher, and a permanent implant (Becker) can be inserted right away.
The breast can also be reconstructed with body tissue from areas with extra skin and fat, like the tummy, buttocks and back. The tissue being removed is called "a flap". Common sites to acquire the flap are the lower tummy and the lotissimus dorsi muscle from the back.
This procedure can be complicated due to implant infection, a contraction of a surface of an implant, silicon leaks and anesthetic complications.
You'll need to stay in hospital 2-7 days after the surgery, while you may feel pain and weakness for a week or two. Complete recovery may take up to 6 weeks, depending on the surgery. You may have an unusual sensation in the breast that would usually disappear over time. In most cases there could be a slight asymmetry between the breasts, however, most women report a significant improvement in their social life and self esteem.
Other Breast Reconstruction Procedures
All Breast Procedures
Breast Reconstruction Jordan (current)
Jordan Breast Lift
Jordan Breast Implants
Jordan Implant Removal
Jordan Armpit Incision
More Jordan info...
Jordan Other destinations
Jerash — one of the largest Roman ruins in the Middle East
Kerak — site of a once-mighty Crusader castle
Madaba — known for its mosaic map of Jerusalem
Petra — Jordan's top attraction, an ancient city carved out of sandstone
Wadi Rum — barren, isolated and beautiful, granite cliffs contrasting with desert sand
Dead Sea — The lowest point on earth and the most saline sea
Dana Nature Reserve — Stay in a village little changed since the 15th century, enjoy unforgettable hiking in an offshoot of the Great Rift.
Jordan Cities
Amman — capital of the kingdom
Zarqa — second largest second in the kingdom
Irbid — third largest city in the north of the kingdom
Aqaba — located on the Gulf of Aqaba / Eilat, with links to the Sinai and the Red Sea
Plastic Surgery News...
- The European Medicines Agency (EMEA) has recommended the approval of Thalidomide Pharmion (thalidomide) for the treatment of multiple myeloma, a rare cancer of the bone marrow. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Thalidomide Pharmion® in combination with melphalan and prednisone outweigh its risks for the first-line treatment of multiple myeloma for patients over 65 years of age or who cannot be treated with high-dose chemotherapy.
Thalidomide is teratogenic and because of this, the CHMP has consulted representatives of thalidomide victims and myeloma patient groups from across the European Union to develop measures that can effectively minimise the risk of foetal exposure to thalidomide. The CHMP has approved a risk management plan that includes a number of actions intended to prevent pregnancies in women being treated with thalidomide and exposure of unborn children to the medicine. For example, all women of child-bearing potential who are treated with Thalidomide Pharmion must undergo pregnancy tests before, during and after treatment, in addition to using selected and effective contraception.
Subject to the granting of a marketing authorisation by the European Commission, Thalidomide Pharmion will only be available by prescription, and treatment will be initiated and monitored by a doctor who has experience in the treatment of multiple myeloma. A clear warning will be printed on the boxes containing the medicine, indicating that Thalidomide Pharmion causes birth defects and foetal death.
Educational materials will be provided to healthcare professionals and patients by Pharmion Ltd prior to the launch of Thalidomide Pharmion in each Member State to ensure the safe use of the product.
- The Committee for Medicinal Products for Human Use (CHMP) has recommended the addition of a new contraindication for rosiglitazone-containing medicines (Avandia®, Avandamet®, Avaglim®), stating that rosiglitazone must not be used in patients with an acute coronary syndrome, such as angina or some types of myocardial infarction. The CHMP also recommended the inclusion of a new warning stating that rosiglitazone is not recommended in patients with ischaemic heart disease and/or peripheral artery disease.
The recommended changes to the product information have been made as a follow-up measure to the re-assessment of the benefits and risks of rosiglitazone and pioglitazone. This re-assessment was finalised by the CHMP in October 2007, concluding that the benefits of both medicines continued to outweigh their risks in their approved indications, but that the product information for rosiglitazone should be changed.
The CHMP and its Efficacy Working Party are currently re-examining their existing ‘Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus’ to decide whether changes are needed. An announcement on this is expected in February.
Nb: Avaglim (rosiglitazone and glimepiride) is not licensed in the UK.